Submissions for variant NM_001609.4(ACADSB):c.303+1G>A

gnomAD frequency: 0.00037  dbSNP: rs147936696

Total submissions: 10

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000498442	SCV000589304	pathogenic	not provided	2023-03-02	criteria provided, single submitter	clinical testing	Canonical splice site variant predicted to result in a null allele in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 31980526, 31589614, 20547083, 33727708)
Invitae	RCV000185535	SCV000830358	pathogenic	Deficiency of 2-methylbutyryl-CoA dehydrogenase	2023-12-19	criteria provided, single submitter	clinical testing	This sequence change affects a donor splice site in intron 3 of the ACADSB gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ACADSB are known to be pathogenic (PMID: 20547083, 26284228). This variant is present in population databases (rs147936696, gnomAD 0.05%). Disruption of this splice site has been observed in individuals with short/branched chain acyl-CoA dehydrogenase (SBCAD) deficiency (PMID: 20547083). This variant is also known as IVS3+1G>A. ClinVar contains an entry for this variant (Variation ID: 203367). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Eurofins Ntd Llc (ga)	RCV000498442	SCV000854866	likely pathogenic	not provided	2017-08-29	criteria provided, single submitter	clinical testing
Illumina Laboratory Services, Illumina	RCV000185535	SCV000915460	likely pathogenic	Deficiency of 2-methylbutyryl-CoA dehydrogenase	2018-12-03	criteria provided, single submitter	clinical testing	The ACADSB c.303+1G>A variant occurs in a canonical splice site (donor) and is therefore predicted to disrupt or distort the normal gene product. The c.303+1G>A variant has been reported in one study in which it was found in a homozygous state in two individuals with acyl-CoA dehydrogenase deficiency, oneof whom was symptomatic and the other asymptomatic newborn (Alfardan et al. 2010). Control data are unavailable for this variant, which is reported at a frequency of 0.000931 in the European American population of the Exome Sequencing Project. Based on the potential impact of splice donor variants and the clinical evidence, the c.303+1G>A variant is classified as likely pathogenic for acyl-CoA dehydrogenase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
CeGaT Center for Human Genetics Tuebingen	RCV000498442	SCV001148113	uncertain significance	not provided	2018-08-01	criteria provided, single submitter	clinical testing
Centre for Mendelian Genomics, University Medical Centre Ljubljana	RCV000185535	SCV001369367	pathogenic	Deficiency of 2-methylbutyryl-CoA dehydrogenase	2019-11-12	criteria provided, single submitter	clinical testing	This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PS1.
Revvity Omics, Revvity	RCV000185535	SCV002021263	likely pathogenic	Deficiency of 2-methylbutyryl-CoA dehydrogenase	2022-06-01	criteria provided, single submitter	clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000185535	SCV004241121	likely pathogenic	Deficiency of 2-methylbutyryl-CoA dehydrogenase	2023-12-15	criteria provided, single submitter	clinical testing	Variant summary: ACADSB c.303+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: One predict the variant abolishes a 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00025 in 251174 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in ACADSB causing Deficiency of 2-methylbutyryl-CoA Dehydrogenase (0.00025 vs 0.0011), allowing no conclusion about variant significance. c.303+1G>A has been reported in the literature in two homozygous individuals, an asymptomatic infant and a symptomatic individual, both with Deficiency of 2-methylbutyryl-CoA Dehydrogenase(Alfardan_2010). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 20547083). Eight submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified as pathogenic/likely pathogenic (n=7) and VUS (n=1). Based on the evidence outlined above, the variant was classified as likely pathogenic.
Division of Human Genetics, Children's Hospital of Philadelphia	RCV000185535	SCV000238410	pathogenic	Deficiency of 2-methylbutyryl-CoA dehydrogenase	2014-07-17	no assertion criteria provided	research	This patient is a carrier of a heterozygous pathogenic variant in the ACADSB gene associated with 2-methylbutyrylglycinuria. The ACADSB variant (c.303+1G>A) identified in this patient is located in the first intronic position of the donor splice site and, therefore, meets the criteria for a pathogenic variant.
OMIM	RCV000185535	SCV001335593	pathogenic	Deficiency of 2-methylbutyryl-CoA dehydrogenase	2020-06-11	no assertion criteria provided	literature only